FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308138214> ?p ?o ?g. }

• W4308138214 endingPage "A797" @default.
• W4308138214 startingPage "A796" @default.
• W4308138214 abstract "Abstract Thyroid cancer is the most prevalent endocrine malignancy and is estimated to have affected 52,890 individuals in the United States in the year 2020. Papillary thyroid cancer (PTC) accounts for up to 80% of all thyroid cancer diagnoses. Within PTC, BRAFV600E is the most common mutation in adults and the second most common mutation in pediatrics. While there are several validated human thyroid cancer cell lines harboring BRAF mutations, no pediatric derived cell line has been established to date, limiting generalizations in pediatric disease. Patient-derived pre-clinical models are valuable tools but are limited due to their need to be studied in vitro or in an immunocompromised host. However, in vivo mouse models recapitulate the complex interactions between tumor cells, the immune system, and components of the microenvironment, allowing more comprehensive investigation of thyroid oncogenesis and response to therapy. In this study we describe a new subcutaneous mouse model that can be used to understand differences between pediatric onset and adult onset PTC. We have developed multiple independent, congenic murine cell lines from different stages of thyroid cancer progression. Two independent BRAFV600E-driven cell lines harboring the same genetic mutations were utilized in this study, one representing a well-differentiated tumor (WD) and one representing a poorly-differentiated tumor (PD). Despite coming from different stages of disease, both cell lines showed similar expression of the thyroid specific genes: Pax8, Ttf1, Tg, and Slc5a5, but expression of Pax8, Tg, and Slc5a5 was lower compared to WT thyrocytes. Activation of the Pi3Kinase pathway and the Akt Pathway were assessed via western blot analysis. The WD cell line had increased pERK activation compared to the PD cell line, and the PD cell line had increased pAKT compared to WD cell line. Both cell lines were injected subcutaneously into the hind flank of Wt SJV129 mice of pediatric age (4-5 weeks) and adult age (20-22 weeks). These animals were monitored for 10 weeks post injection. While the PD cell line developed tumors at approximately the same rate and penetrance in both age groups, tumors reached end point more rapidly in the adult cohort. Adult hosts injected with the WD cell line developed tumors more rapidly than in pediatric hosts, however, tumors receded in both cohorts. While adult and pediatric thyroid cancer share common driving mutations, there are distinct differences in disease pathogenesis between these patient populations. There are known differences in the immune system, metabolism, and other variables between pediatrics and adults. However, it is unknown what causes the difference in PTC pathogenesis between pediatric versus adult patients. We believe these new models provide a great opportunity to evaluate the role of age in PTC development and progression. Presentation: Saturday, June 11, 2022 12:15 p.m. - 12:30 p.m." @default.
• W4308138214 created "2022-11-08" @default.
• W4308138214 creator A5011267630 @default.
• W4308138214 creator A5021115774 @default.
• W4308138214 creator A5033120610 @default.
• W4308138214 creator A5044427947 @default.
• W4308138214 creator A5064547733 @default.
• W4308138214 creator A5084779919 @default.
• W4308138214 date "2022-11-01" @default.
• W4308138214 modified "2023-09-25" @default.
• W4308138214 title "OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer" @default.
• W4308138214 doi "https://doi.org/10.1210/jendso/bvac150.1648" @default.
• W4308138214 hasPublicationYear "2022" @default.
• W4308138214 type Work @default.
• W4308138214 citedByCount "0" @default.
• W4308138214 crossrefType "journal-article" @default.
• W4308138214 hasAuthorship W4308138214A5011267630 @default.
• W4308138214 hasAuthorship W4308138214A5021115774 @default.
• W4308138214 hasAuthorship W4308138214A5033120610 @default.
• W4308138214 hasAuthorship W4308138214A5044427947 @default.
• W4308138214 hasAuthorship W4308138214A5064547733 @default.
• W4308138214 hasAuthorship W4308138214A5084779919 @default.
• W4308138214 hasBestOaLocation W43081382141 @default.
• W4308138214 hasConcept C104317684 @default.
• W4308138214 hasConcept C121608353 @default.
• W4308138214 hasConcept C124224327 @default.
• W4308138214 hasConcept C126322002 @default.
• W4308138214 hasConcept C127716648 @default.
• W4308138214 hasConcept C143998085 @default.
• W4308138214 hasConcept C2776107976 @default.
• W4308138214 hasConcept C2779399171 @default.
• W4308138214 hasConcept C2779761222 @default.
• W4308138214 hasConcept C2781461381 @default.
• W4308138214 hasConcept C2993561819 @default.
• W4308138214 hasConcept C502942594 @default.
• W4308138214 hasConcept C526584372 @default.
• W4308138214 hasConcept C54355233 @default.
• W4308138214 hasConcept C555283112 @default.
• W4308138214 hasConcept C68838962 @default.
• W4308138214 hasConcept C71924100 @default.
• W4308138214 hasConcept C86339819 @default.
• W4308138214 hasConcept C86803240 @default.
• W4308138214 hasConceptScore W4308138214C104317684 @default.
• W4308138214 hasConceptScore W4308138214C121608353 @default.
• W4308138214 hasConceptScore W4308138214C124224327 @default.
• W4308138214 hasConceptScore W4308138214C126322002 @default.
• W4308138214 hasConceptScore W4308138214C127716648 @default.
• W4308138214 hasConceptScore W4308138214C143998085 @default.
• W4308138214 hasConceptScore W4308138214C2776107976 @default.
• W4308138214 hasConceptScore W4308138214C2779399171 @default.
• W4308138214 hasConceptScore W4308138214C2779761222 @default.
• W4308138214 hasConceptScore W4308138214C2781461381 @default.
• W4308138214 hasConceptScore W4308138214C2993561819 @default.
• W4308138214 hasConceptScore W4308138214C502942594 @default.
• W4308138214 hasConceptScore W4308138214C526584372 @default.
• W4308138214 hasConceptScore W4308138214C54355233 @default.
• W4308138214 hasConceptScore W4308138214C555283112 @default.
• W4308138214 hasConceptScore W4308138214C68838962 @default.
• W4308138214 hasConceptScore W4308138214C71924100 @default.
• W4308138214 hasConceptScore W4308138214C86339819 @default.
• W4308138214 hasConceptScore W4308138214C86803240 @default.
• W4308138214 hasIssue "Supplement_1" @default.
• W4308138214 hasLocation W43081382141 @default.
• W4308138214 hasLocation W43081382142 @default.
• W4308138214 hasOpenAccess W4308138214 @default.
• W4308138214 hasPrimaryLocation W43081382141 @default.
• W4308138214 hasRelatedWork W1843162183 @default.
• W4308138214 hasRelatedWork W1964071376 @default.
• W4308138214 hasRelatedWork W2011233230 @default.
• W4308138214 hasRelatedWork W2035974695 @default.
• W4308138214 hasRelatedWork W2144287208 @default.
• W4308138214 hasRelatedWork W2309573236 @default.
• W4308138214 hasRelatedWork W2329903233 @default.
• W4308138214 hasRelatedWork W2801297856 @default.
• W4308138214 hasRelatedWork W3121951442 @default.
• W4308138214 hasRelatedWork W4308138214 @default.
• W4308138214 hasVolume "6" @default.
• W4308138214 isParatext "false" @default.
• W4308138214 isRetracted "false" @default.
• W4308138214 workType "article" @default.